Top-News
Neuester,
zuletzt geles. Beitrag
Antworten | Hot-Stocks-Forum Übersicht
Zurück
Weiter
... 25 26 27 29 30 31
Antworten | Hot-Stocks-Forum Übersicht
Zurück
Weiter ... 25 26 27 29 30 31
$$ D E T O N A T I O N $$
Beiträge:
771
Zugriffe: 180.472 / Heute: 21
Zugriffe: 180.472 / Heute: 21
|
|
| ||||||||||||||||||||
Werbung
Entdecke die beliebtesten ETFs von SPDR
SPDR MSCI Europe Financials UCITS ETF
Perf. 12M: +36,26%
SPDR MSCI Europe Communication Services UCITS ETF
Perf. 12M: +27,41%
SPDR MSCI Europe Utilities UCITS ETF
Perf. 12M: +26,52%
SPDR MSCI Europe Industrials UCITS ETF
Perf. 12M: +23,67%
SPDR MSCI World Financials UCITS ETF
Perf. 12M: +22,28%
BOCA RATON, Fla., Oct 2, 2007 (PrimeNewswire via COMTEX) -- Genesis Technology Group, Inc. (GTEC:genesis technology group inc com
News, chart, profile, more
Last: 0.20+0.10+90.48%
9:51am 10/02/2007
Delayed quote dataAdd to portfolio
Analyst
Create alertInsider
Discuss
Financials
Sponsored by:
GTEC 0.20, +0.10, +90.5%) has entered into a reverse merger with a company that owns and controls Laiyang Jiangbo Pharmaceuticals Co., Ltd. ("LJPC"), a Chinese pharmaceutical company. For its fiscal year ended June 30, 2007, the Company reported total revenue of $76,000,000; net income of $22,000,000; total assets of $55,000,000; and cash on hand of $17,000,000.
Located in a coastal city in Shandong Province, LJPC underwent an official audit by Moore Stephens Wurth Frazer and Torbet, LLP of Los Angeles, California, in addition to a rigorous due diligence process by Genesis management and consultants.
Based on research performed by a U.S. consulting firm and merchant bank, which inspected the LJPC facilities in Laiyang City last month, revenues have grown by an average of 187% over the previous two years, and net income has risen by an average of 748% over the same period.
Mr. Gary L. Wolfson, Genesis CEO since August 2002, reported: "Since early 2003, Genesis management has earnestly and methodically sought a merger partner. Under the guidance of Dr. Shaohua Tan in China, we screened numerous candidates, and none could match the strength and potential of Laiyang Jiangbo Pharmaceuticals.
"It is an honor to turn over the future of the merged company to the leadership of Mr. Wubo Cao and his experienced team. Mr. Cao shall serve as the Chairman and Chief Executive Officer. It is our belief that the existing Genesis shareholders will be rewarded for their patience and dedication. In many ways, this merger is the crowning achievement of many years of effort and planning by Genesis management.
News, chart, profile, more
Last: 0.20+0.10+90.48%
9:51am 10/02/2007
Delayed quote dataAdd to portfolio
Analyst
Create alertInsider
Discuss
Financials
Sponsored by:
GTEC 0.20, +0.10, +90.5%) has entered into a reverse merger with a company that owns and controls Laiyang Jiangbo Pharmaceuticals Co., Ltd. ("LJPC"), a Chinese pharmaceutical company. For its fiscal year ended June 30, 2007, the Company reported total revenue of $76,000,000; net income of $22,000,000; total assets of $55,000,000; and cash on hand of $17,000,000.
Located in a coastal city in Shandong Province, LJPC underwent an official audit by Moore Stephens Wurth Frazer and Torbet, LLP of Los Angeles, California, in addition to a rigorous due diligence process by Genesis management and consultants.
Based on research performed by a U.S. consulting firm and merchant bank, which inspected the LJPC facilities in Laiyang City last month, revenues have grown by an average of 187% over the previous two years, and net income has risen by an average of 748% over the same period.
Mr. Gary L. Wolfson, Genesis CEO since August 2002, reported: "Since early 2003, Genesis management has earnestly and methodically sought a merger partner. Under the guidance of Dr. Shaohua Tan in China, we screened numerous candidates, and none could match the strength and potential of Laiyang Jiangbo Pharmaceuticals.
"It is an honor to turn over the future of the merged company to the leadership of Mr. Wubo Cao and his experienced team. Mr. Cao shall serve as the Chairman and Chief Executive Officer. It is our belief that the existing Genesis shareholders will be rewarded for their patience and dedication. In many ways, this merger is the crowning achievement of many years of effort and planning by Genesis management.
Genesis Technology Group Merges With Chinese Pharmaceutical: 'Crowning Achievement' Says Management
BOCA RATON, Fla., Oct. 2, 2007 (PRIME NEWSWIRE) -- Genesis Technology Group, Inc. (OTCBB:GTEC) has entered into a reverse merger with a company that owns and controls Laiyang Jiangbo Pharmaceuticals Co., Ltd. ("LJPC"), a Chinese pharmaceutical company. For its fiscal year ended June 30, 2007, the Company reported total revenue of $76,000,000; net income of $22,000,000; total assets of $55,000,000; and cash on hand of $17,000,000.
Located in a coastal city in Shandong Province, LJPC underwent an official audit by Moore Stephens Wurth Frazer and Torbet, LLP of Los Angeles, California, in addition to a rigorous due diligence process by Genesis management and consultants.
Based on research performed by a U.S. consulting firm and merchant bank, which inspected the LJPC facilities in Laiyang City last month, revenues have grown by an average of 187% over the previous two years, and net income has risen by an average of 748% over the same period.
Mr. Gary L. Wolfson, Genesis CEO since August 2002, reported: "Since early 2003, Genesis management has earnestly and methodically sought a merger partner. Under the guidance of Dr. Shaohua Tan in China, we screened numerous candidates, and none could match the strength and potential of Laiyang Jiangbo Pharmaceuticals.
BOCA RATON, Fla., Oct. 2, 2007 (PRIME NEWSWIRE) -- Genesis Technology Group, Inc. (OTCBB:GTEC) has entered into a reverse merger with a company that owns and controls Laiyang Jiangbo Pharmaceuticals Co., Ltd. ("LJPC"), a Chinese pharmaceutical company. For its fiscal year ended June 30, 2007, the Company reported total revenue of $76,000,000; net income of $22,000,000; total assets of $55,000,000; and cash on hand of $17,000,000.
Located in a coastal city in Shandong Province, LJPC underwent an official audit by Moore Stephens Wurth Frazer and Torbet, LLP of Los Angeles, California, in addition to a rigorous due diligence process by Genesis management and consultants.
Based on research performed by a U.S. consulting firm and merchant bank, which inspected the LJPC facilities in Laiyang City last month, revenues have grown by an average of 187% over the previous two years, and net income has risen by an average of 748% over the same period.
Mr. Gary L. Wolfson, Genesis CEO since August 2002, reported: "Since early 2003, Genesis management has earnestly and methodically sought a merger partner. Under the guidance of Dr. Shaohua Tan in China, we screened numerous candidates, and none could match the strength and potential of Laiyang Jiangbo Pharmaceuticals.
Text zur Anzeige gekürzt. Gesamten Beitrag anzeigen »
Hallo,
ich lese im folgenden Forum öfters was über ein Ziel von 5 Dollar.
Desweiteren stehen da Fälle von Aktien, mit denen ähnliches passiert ist und welche dann z.B. von 0,02 auf 11,00 gestiegen sind.
investorshub.advfn.com/boards/board.asp?board_id=743
gruß
ich lese im folgenden Forum öfters was über ein Ziel von 5 Dollar.
Desweiteren stehen da Fälle von Aktien, mit denen ähnliches passiert ist und welche dann z.B. von 0,02 auf 11,00 gestiegen sind.
investorshub.advfn.com/boards/board.asp?board_id=743
gruß
Anzeige: EchoIQ
Das KI-Unternehmen, das Ihr Herz retten – und Ihr Portfolio beflügeln könnte
Profile of LJPC
For its fiscal year ended June 30, 2007, LJPC reported total revenue of $76,000,000; net income of $22,000,000; total assets of $55,000,000; and cash on hand of $17,000,000. Revenues have grown by an average of 187% over the previous two years, and net income has risen by an average of 748% over the same period, based on research by a U.S. consulting firm and merchant bank, which inspected the LJPC facilities in Laiyang City in September.
LJPC's fiscal years, as audited by MSWFT, run from July 1st to June 30th of each calendar year. Moore Stephens will serve as GTEC's auditor going forward.
An independent U.S. financial advisor accompanied Dr. Tan and Mr. Wolfson to LJPC last month and provided the following information:
*
Laiyang Jiangbo Pharmaceuticals was established in July 2003 and is a medium-sized pharmaceutical company that is currently producing and selling five (5) Government approved drugs with several in the pipeline awaiting final approval. The company is located in Northeast China in an Economic Development Zone, Laiyang City, Shandong Province.
*
The company has 440 full time sales representatives and 620 part time representatives located in all major commerce areas across China
*
The company has numerous GMP (Chinese State Drug Administration - SDA) approved manufacturing facilities and production lines and is approved to produce tablets, capsules and granules. In 2007, LJPC produced 300 million tablets, 50 million bags of granule and 50 million capsules. Company's top four products include Clarithromycin sustained-release tablets, Itopride Hydrochloride granules, Ciprofloxacin Hydrochloride tablets, and Paracetamol tablets.
For its fiscal year ended June 30, 2007, LJPC reported total revenue of $76,000,000; net income of $22,000,000; total assets of $55,000,000; and cash on hand of $17,000,000. Revenues have grown by an average of 187% over the previous two years, and net income has risen by an average of 748% over the same period, based on research by a U.S. consulting firm and merchant bank, which inspected the LJPC facilities in Laiyang City in September.
LJPC's fiscal years, as audited by MSWFT, run from July 1st to June 30th of each calendar year. Moore Stephens will serve as GTEC's auditor going forward.
An independent U.S. financial advisor accompanied Dr. Tan and Mr. Wolfson to LJPC last month and provided the following information:
*
Laiyang Jiangbo Pharmaceuticals was established in July 2003 and is a medium-sized pharmaceutical company that is currently producing and selling five (5) Government approved drugs with several in the pipeline awaiting final approval. The company is located in Northeast China in an Economic Development Zone, Laiyang City, Shandong Province.
*
The company has 440 full time sales representatives and 620 part time representatives located in all major commerce areas across China
*
The company has numerous GMP (Chinese State Drug Administration - SDA) approved manufacturing facilities and production lines and is approved to produce tablets, capsules and granules. In 2007, LJPC produced 300 million tablets, 50 million bags of granule and 50 million capsules. Company's top four products include Clarithromycin sustained-release tablets, Itopride Hydrochloride granules, Ciprofloxacin Hydrochloride tablets, and Paracetamol tablets.
To call the merger the "crowning achievement" of management is no exaggeration.
What is the Valuation of Genesis Pharmaceutica Enterprises, Inc?
GTEC has just announced a reverse merger of a profitable Chinese company that earned $22 Million in the last 12 months...and has $17 million cash in the bank. I don't know exactly what numbers you multiply to calculate a companies value...but surely any company must be worth 15-20 times its annual net income. If we do that, we get the following totals:
$22 million times 15 ='s a valuation of $330,000,000
$22 million times 20 ='s a valuation of $440,000,000
$22 Million times 30 ='s a valuation of $660,000,000
On a per share basis that would give us between .83, $1.10 and $1.65 per share.
That's waaaay higher than current share price.....
PLUS GTEC's prior assets will be distributed to GTEC shareholders. Their book value was $7.6 million in last 10Q. With 100,000,000 shares to distribute the assets to, that comes out to 76 cents per share. NOTICE, the valuations they used were minimal not even current market prices. Current market price would put the value of this distribution at buck or two. Scary good.
I think GTEC will see $3-5.00 probably much more before all is done.
PLUS we have a growing profitable pharmeceutical company.
I just can't see selling too many of my shares until this distribution is made.
GTEC has just announced a reverse merger of a profitable Chinese company that earned $22 Million in the last 12 months...and has $17 million cash in the bank. I don't know exactly what numbers you multiply to calculate a companies value...but surely any company must be worth 15-20 times its annual net income. If we do that, we get the following totals:
$22 million times 15 ='s a valuation of $330,000,000
$22 million times 20 ='s a valuation of $440,000,000
$22 Million times 30 ='s a valuation of $660,000,000
On a per share basis that would give us between .83, $1.10 and $1.65 per share.
That's waaaay higher than current share price.....
PLUS GTEC's prior assets will be distributed to GTEC shareholders. Their book value was $7.6 million in last 10Q. With 100,000,000 shares to distribute the assets to, that comes out to 76 cents per share. NOTICE, the valuations they used were minimal not even current market prices. Current market price would put the value of this distribution at buck or two. Scary good.
I think GTEC will see $3-5.00 probably much more before all is done.
PLUS we have a growing profitable pharmeceutical company.
I just can't see selling too many of my shares until this distribution is made.
GTEC- from previous reverse mergers that GTEC falls into the same category,
shellstockreview,
how about a Shell Stock that went from $0.10 to $11.20 in two days, and later traded as high as $30
But after completing a Reverse Merger, they can explode in price and increase in value by 10 times, 20 times, and possibly over 100 times their original share price!
GTEC-merger company (LJPC) is believed to be only the second Chinese company in the country to obtain CRSC Regulation No. 106 approval from the
government, which officially permits the completion of such a merger with a U.S. public company.
GTEC- Laiyang Jiangbo Pharmaceuticals Co., Ltd. ("LJPC"),For its fiscal year ended June 30, 2007, LJPC reported total revenue of $76,000,000; net income of $22,000,000; total assets of $55,000,000; and cash on hand of $17,000,000. Revenues have grown by an average of 187% over the previous two years, and net income has risen by an average of 748% over the same period, based on research by a U.S. consulting firm and merchant bank, which inspected the LJPC facilities in Laiyang City in early September.
shellstockreview,
how about a Shell Stock that went from $0.10 to $11.20 in two days, and later traded as high as $30
But after completing a Reverse Merger, they can explode in price and increase in value by 10 times, 20 times, and possibly over 100 times their original share price!
GTEC-merger company (LJPC) is believed to be only the second Chinese company in the country to obtain CRSC Regulation No. 106 approval from the
government, which officially permits the completion of such a merger with a U.S. public company.
GTEC- Laiyang Jiangbo Pharmaceuticals Co., Ltd. ("LJPC"),For its fiscal year ended June 30, 2007, LJPC reported total revenue of $76,000,000; net income of $22,000,000; total assets of $55,000,000; and cash on hand of $17,000,000. Revenues have grown by an average of 187% over the previous two years, and net income has risen by an average of 748% over the same period, based on research by a U.S. consulting firm and merchant bank, which inspected the LJPC facilities in Laiyang City in early September.
Das eine Aktie, wo ähnliches passiert ist innerhalb von 2 Tagen von 0,1 auf 11,10 gestiegen ist und dann weiter auf 30,00. Und sich Genesis nach dieser Rückfusion ver-100-fachen könnte....
Dich zwingt ja auch keiner ,ich dgegen bin froh dass ich welche hab((--;
Ich denke das nächste Ziel liegt hete Nachmittag bei 0,30Euro.
Und außer dem gab es in der Vergangenheit viele Werte die als Dreck betitelt wurden
die einige heute gern in ihrem Depot hätten.
Gruß
Ich denke das nächste Ziel liegt hete Nachmittag bei 0,30Euro.
Und außer dem gab es in der Vergangenheit viele Werte die als Dreck betitelt wurden
die einige heute gern in ihrem Depot hätten.
Gruß
Es geht gleich los
Realtime-Kursabfrage
Bitte beachten Sie, dass es sich bei den angezeigten Kursen nicht um Realtime-Kurse handelt.
§
§ WKN / ISIN 931506 / US37184Q1022
§ Wertpapierbezeichnung GENESIS TECHNOLOGY GROUP INC.REG.SHS
§ Handelsplatz
Kursdaten (in EUR), Stand: 14:59 Uhr 03.10.2007 Volumen
Letzter Kurs 0,26 k.A.
Geld 0,25 10.000 St.
Brief 0,27 20.000 St.
Realtime-Kursabfrage
Bitte beachten Sie, dass es sich bei den angezeigten Kursen nicht um Realtime-Kurse handelt.
§
§ WKN / ISIN 931506 / US37184Q1022
§ Wertpapierbezeichnung GENESIS TECHNOLOGY GROUP INC.REG.SHS
§ Handelsplatz
Kursdaten (in EUR), Stand: 14:59 Uhr 03.10.2007 Volumen
Letzter Kurs 0,26 k.A.
Geld 0,25 10.000 St.
Brief 0,27 20.000 St.
Es gibt keine neuen Beiträge.
Ich:
|
Neueste Beiträge aus dem EUTEX EUROPEAN TELCO Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
6 | 770 | $$ D E T O N A T I O N $$ | Calibra21 | paris03 | 26.06.12 16:45 | |
| 2 | EUTEX-Insolvenzverfahren eröffnet | zoka101 | Robin | 30.03.07 13:58 | ||
| 2 | Eutex bald wieder über EUR 1,00 | Top1 | Top1 | 15.01.07 10:23 | ||
| 41 | EUTEX heute gekauft - Top-Chance | charly2 | Top1 | 12.01.07 13:38 | ||
| Eutex | PrivateEquity | 16.01.06 14:23 |